Functional evidence from our ORF screen analysis further highlights the biological relevance of BRD4 deregulation in other cancer types, such as medulloblastoma, where targeted therapies against BRD4, including bromodomain and extra-terminal motif-bromodomain inhibitors, hold clinical promise.23 This evidence concerns the gene BRD4 and cancer.